Drug Information
Side Effects > Rozerem

Rozerem Side Effects

Generic name: ramelteon

Generic Name: Ramelteon

Please note - some side effects for Rozerem may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).


For the consumer

For the professional

By body system

Side Effects of Rozerem - for the consumer


Rozerem

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Rozerem:

Diarrhea; dizziness; drowsiness; fatigue; nausea; tiredness.

Seek medical attention right away if any of these SEVERE side effects occur when using Rozerem:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the hands, legs, mouth, face, lips, eyes, throat, or tongue; unusual hoarseness); absence of a menstrual cycle; decreased sex drive; difficulty swallowing or breathing; fever; hallucinations; headache; irregular heartbeat; memory problems; mental or mood changes (eg, abnormal thinking, agitation, anxiety, behavior changes, new or worsening depression); muscle aches; muscle or joint pain; pounding in the chest; problems with fertility; shortness of breath; suicidal thoughts or behaviors; unexplained breast milk production; vision changes; vomiting; worsening of sleeplessness.

Top

For the professional


Rozerem

Overview

The data described in this section reflect exposure to Rozerem in 4251 subjects, including 346 exposed for 6 months or longer, and 473 subjects for one year.

Adverse Reactions Resulting in Discontinuation of Treatment

Six percent of the 3594 individual subjects exposed to Rozerem in clinical studies discontinued treatment owing to an adverse event, compared with 2% of the 1370 subjects receiving placebo. The most frequent adverse events leading to discontinuation in subjects receiving Rozerem were somnolence (0.8%), dizziness (0.5%), nausea (0.3%), fatigue (0.3%), headache (0.3%), and insomnia (0.3%).

Rozerem Most Commonly Observed Adverse Events in Phase 1-3 trials

Table 1 displays the incidence of adverse events during the Phase 1 through 3 trials.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of other drugs, and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Table 1. Incidence (% of subjects) of Treatment-Emergent Adverse Events in Phase 1-3 Studies
MedDRA Preferred Term Placebo (n=1370) Ramelteon 8 mg (n=1250)
Headache NOS 7% 7%
Somnolence 3% 5%
Fatigue 2% 4%
Dizziness 3% 5%
Nausea 2% 3%
Insomnia exacerbated 2% 3%
Upper respiratory tract infection NOS 2% 3%
Diarrhea NOS 2% 2%
Myalgia 1% 2%
Depression 1% 2%
Dysgeusia 1% 2%
Arthralgia 1% 2%
Influenza 0 1%
Blood cortisol decreased 0 1%
Top

By body system


Gastrointestinal side effects

Gastrointestinal side effects for ramelteon in relation to placebo therapy have included nausea (3% vs. 2%), diarrhea (2% vs. 2%), and dysgeusia (2% vs. 1%).


Musculoskeletal side effects

Musculoskeletal side effects for ramelteon compared to placebo therapy have included myalgia (2% vs. 1%) and arthralgia (2% vs. 1%).


Nervous system side effects

Nervous system side effects for ramelteon compared to placebo therapy have included somnolence (5% vs. 3%), dizziness (5% vs. 3%), and exacerbated insomnia (3% vs. 2%).


Other side effects

Other side effects for ramelteon compared to placebo therapy have included headache (7% vs. 7%), fatigue (4% vs. 2%) and influenza (1% vs. 0%).


Psychiatric side effects

Psychiatric side effects for ramelteon compared to placebo therapy have included depression (2% vs. 1%). Hallucinations, as well as behavioral changes such as bizarre behavior, agitation, and mania have also been reported with ramelteon use.

A variety of cognitive and behavior changes have been reported to occur in association with the use of hypnotics. In primarily depressed patients, worsening of depression (including suicidal ideation and completed suicides) has been reported in association with the use of hypnotics.

Complex behaviors such as "sleep-driving" (i.e., driving while not fully awake after ingestion of a hypnotic) and other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex), with amnesia for the event, have been reported in association with hypnotic use. Complex behaviors have been reported with the use of ramelteon.


Respiratory side effects

Respiratory side effects for ramelteon compared to placebo therapy have included upper respiratory tract infection (3% vs. 2%). Pharyngolaryngeal pain (1.9%) has also been reported.


Endocrine side effects

Endocrine side effects for ramelteon compared to placebo therapy have included decreased blood cortisol level (1% vs. 0%). Compared with placebo, increases in serum prolactin levels have been reported in patients receiving a 16 mg dose (19% vs 32%, respectively) of ramelteon.


General side effects

In general, ramelteon has been well tolerated with most side effects described as mild or moderate in severity. In clinical trials, approximately 5% of patients discontinued treatment with ramelteon due to side effects. There have been no reports of cognitive impairment, rebound insomnia following discontinuation of ramelteon, withdrawal effects, or abuse.

Top

More resources:

Drugs.com Rozerem

PDR Rozerem

MedFacts Rozerem

Micromedex Rozerem - Includes detailed dosage instructions.

FDA Rozerem

Facts & Comparisons Ramelteon

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


MedNotes
Advertisement

(web2)